Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALVARO M MURCIA

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1104822261
CMS profile
231014
Location
PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$606.94

32 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $594.49 31
Education $12.45 1

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALVARO M MURCIA

NPI 1104822261 · CMS profile ID 231014

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

PEMBROKE PINES, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104822261?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALVARO M MURCIA, NPI 1104822261, CMS profile ID 231014. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104822261?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ALVARO M MURCIA, NPI 1104822261, CMS profile ID 231014. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104822261?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ALVARO M MURCIA, NPI 1104822261, CMS profile ID 231014, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1104822261?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

32 matching records · $606.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 32 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–32 of 32.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $15.0411/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659067713 CMS
Regeneron Healthcare Solutions, Inc. $18.0711/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673445151 CMS
Janssen Pharmaceuticals, Inc $16.3311/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659067709 CMS
AstraZeneca Pharmaceuticals LP $22.9510/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685783351 CMS
Regeneron Healthcare Solutions, Inc. $20.3310/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673445149 CMS
Janssen Pharmaceuticals, Inc $17.4809/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659067705 CMS
PFIZER INC. $13.9109/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672889137 CMS
Amarin Pharma Inc. $18.2008/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699185259 CMS
AstraZeneca Pharmaceuticals LP $23.5407/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685065653 CMS
Janssen Pharmaceuticals, Inc $23.3007/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659067701 CMS
PFIZER INC. $13.9107/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672646783 CMS
Janssen Pharmaceuticals, Inc $17.2006/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659067699 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.5405/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700463627 CMS
E.R. Squibb & Sons, L.L.C. $19.3905/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651371935 CMS
Regeneron Healthcare Solutions, Inc. $12.4505/13/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673445147 CMS
Regeneron Healthcare Solutions, Inc. $20.2105/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673445145 CMS
Janssen Pharmaceuticals, Inc $18.3305/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659067695 CMS
SANOFI-AVENTIS U.S. LLC $24.4204/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694301349 CMS
AstraZeneca Pharmaceuticals LP $16.9804/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685637409 CMS
PFIZER INC. $13.9104/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672044197 CMS
Regeneron Healthcare Solutions, Inc. $27.1104/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673445143 CMS
Janssen Pharmaceuticals, Inc $16.6404/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659067691 CMS
Novartis Pharmaceuticals Corporation $18.0703/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659762372 CMS
Amarin Pharma Inc. $18.5803/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699104805 CMS
Amgen Inc. $20.0003/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663206187 CMS
Regeneron Healthcare Solutions, Inc. $28.5302/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673445141 CMS
PFIZER INC. $13.9102/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672013409 CMS
AstraZeneca Pharmaceuticals LP $18.2302/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685210629 CMS
ARBOR PHARMACEUTICALS, INC. $14.4201/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697365623 CMS
SANOFI-AVENTIS U.S. LLC $14.2801/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694272427 CMS
Janssen Pharmaceuticals, Inc $17.4801/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659067685 CMS
Regeneron Healthcare Solutions, Inc. $30.2001/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673445139 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $606.94 32
PY2020 $366.85 18
PY2021 $465.58 22
PY2023 $20.75 1
PY2024 $169.48 4
PY2025 $127.06 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $406,482.03 21
PY2024 Principal investigator $1,460,913.18 46
PY2023 Principal investigator $709,095.23 72
PY2022 Principal investigator $649,259.15 51
PY2021 Principal investigator $536,745.12 32
PY2020 Principal investigator $88,190.48 30
PY2019 Principal investigator $148,033.20 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $3,530.28 12/28/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949768769
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,269.00 12/27/2022 Non-covered Recipient Entity
Dbc Rsrch Usa Corp.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885215539
Principal investigator 1 PFIZER INC. $780.00 12/21/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949768553
Principal investigator 1 PFIZER INC. $4,147.00 12/17/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949768773
Principal investigator 1 PFIZER INC. $37,037.00 12/16/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949769027
Principal investigator 1 PFIZER INC. $6,181.31 12/14/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949768771
Principal investigator 1 PFIZER INC. $23,569.00 12/10/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949769079
Principal investigator 1 PFIZER INC. $41,995.85 12/07/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949769081
Principal investigator 1 PFIZER INC. $35,353.50 12/03/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949769123
Principal investigator 1 PFIZER INC. $18,518.50 11/23/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949781595
Principal investigator 1 PFIZER INC. $11,421.40 11/16/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949779077
Principal investigator 1 PFIZER INC. $5,050.50 11/10/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949781811
Principal investigator 1 PFIZER INC. $11,784.50 11/09/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949781849
Principal investigator 1 PFIZER INC. $93.15 11/08/2022 Non-covered Recipient Entity
DBC Research USA
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949761671
Principal investigator 1 PFIZER INC. $18.63 11/01/2022 Non-covered Recipient Entity
DBC Research USA
A PHASE 1 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF COMBINED MODIFIED RNA VACCINE CANDIDATES AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949761139
Principal investigator 1 Becton, Dickinson and Company $3,495.02 10/31/2022 Non-covered Recipient Entity
DBC Research
Triplex No dispute reported 06/30/2026 929560477
Principal investigator 1 PFIZER INC. $11,320.00 10/28/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949788337
Principal investigator 1 PFIZER INC. $844.48 10/27/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949793465
Principal investigator 1 Janssen Pharmaceuticals, Inc $35,280.00 10/26/2022 Non-covered Recipient Entity
Dbc Rsrch Usa Corp.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885215543
Principal investigator 1 PFIZER INC. $844.48 10/14/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949793467
Principal investigator 1 ABBVIE INC. $3,292.60 10/12/2022 Non-covered Recipient Entity
DBC RESEARCH USA CORP
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889814493
Principal investigator 1 PFIZER INC. $55.89 10/03/2022 Non-covered Recipient Entity
DBC Research USA
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949761141
Principal investigator 1 PFIZER INC. $12,667.20 09/30/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949793469
Principal investigator 1 PFIZER INC. $7,384.00 09/28/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949794157
Principal investigator 1 PFIZER INC. $45,601.92 09/24/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949793277
Principal investigator 1 PFIZER INC. $9,714.90 09/09/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949794155
Principal investigator 1 PFIZER INC. $9,111.70 08/17/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949802101
Principal investigator 1 PFIZER INC. $2,125.76 08/16/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949803205
Principal investigator 1 ABBVIE INC. $11,558.90 08/10/2022 Non-covered Recipient Entity
DBC RESEARCH USA CORP
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889805089
Principal investigator 1 Novartis Pharmaceuticals Corporation $330.10 08/04/2022 Non-covered Recipient Entity
DBC RESEARCH USA
AN OPEN-LABEL EXTENSION TRIAL OF THE PHASE III LIPID-LOWERING TRIALS TO ASSESS THE EFFECT OF LONG TERM DOSING OF INCLISIRAN GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH HIGH CARDIOVASCULAR RISK AND ELEVATED LDL-C No dispute reported 06/30/2026 909398195
Principal investigator 1 PFIZER INC. $92,914.90 08/03/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949803609
Principal investigator 1 PFIZER INC. $3,217.76 07/29/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949809959
Principal investigator 1 ABBVIE INC. $3,680.10 07/07/2022 Non-covered Recipient Entity
DBC RESEARCH USA CORP
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889798837
Principal investigator 1 PFIZER INC. $1,324.96 06/29/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949814337
Principal investigator 1 PFIZER INC. $13,120.00 06/16/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 12 RANDOMIZED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949814335
Principal investigator 1 Becton, Dickinson and Company $1,750.00 06/15/2022 Non-covered Recipient Entity
DBC RESEARCH USA CORP
VerFresh No dispute reported 06/30/2026 929560483
Principal investigator 1 PFIZER INC. $4,353.44 06/15/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949814141
Principal investigator 1 ABBVIE INC. $3,350.50 06/08/2022 Non-covered Recipient Entity
DBC RESEARCH USA CORP
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889794205
Principal investigator 1 PFIZER INC. $2,649.92 05/27/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949752047
Principal investigator 1 PFIZER INC. $1,324.96 05/14/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949752051
Principal investigator 1 ABBVIE INC. $1,860.20 05/05/2022 Non-covered Recipient Entity
DBC RESEARCH USA CORP
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889790021
Principal investigator 1 PFIZER INC. $31,186.22 04/29/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949821333
Principal investigator 1 PFIZER INC. $4,164.16 04/14/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949821335
Principal investigator 1 PFIZER INC. $5,299.84 04/01/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949821407
Principal investigator 1 PFIZER INC. $9,140.30 03/16/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949827121
Principal investigator 1 ABBVIE INC. $1,977.00 03/08/2022 Non-covered Recipient Entity
DBC RESEARCH USA CORP
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men No dispute reported 06/30/2026 889779943
Principal investigator 1 PFIZER INC. $31,906.42 02/25/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949829927
Principal investigator 1 PFIZER INC. $62,847.46 02/04/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949829925
Principal investigator 1 ABBVIE INC. $412.50 02/03/2022 Non-covered Recipient Entity
DBC RESEARCH USA CORP
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) No dispute reported 06/30/2026 889775423
Principal investigator 1 PFIZER INC. $14,769.04 01/08/2022 Non-covered Recipient Entity
DBC Research USA Corp
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949831493
Principal investigator 1 ABBVIE INC. $3,632.90 01/06/2022 Non-covered Recipient Entity
DBC RESEARCH USA CORP
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men (TRAVERSE) No dispute reported 06/30/2026 889772517